ArticleGene therapy2013
Cathelicidin protects against Helicobacter pylori colonization and the associated gastritis in mice.
Article in Gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Endogenous cathelicidin protects againstInfection and immunity · 2026Article
- Vitamin D remodels the tumor microenvironment to suppress gastric cancer progression through cancer-associated fibroblasts-secreted exosomal miR-378c targeting KDSR.Archives of pharmacal research · 2026Article
- Anti-urease therapy: a targeted approach to mitigating antibiotic resistance in Helicobacter pylori while preserving the gut microflora.Gut pathogens · 2025Review
- Monocyte-driven inflamm-aging reduces intestinal barrier function in females.Immunity & ageing : I & A · 2024Article
- LncRNA RP11-93B14.5 promotes gastric cancer cell growth through PI3K/AKT signaling pathway.Molecular biotechnology · 2024Article
- Recent Advances in Vitamin D3 Intervention to EradicateJournal of multidisciplinary healthcare · 2024Review
- Control ofMicrobiology spectrum · 2023Article
- Immune Biology and Persistence of Helicobacter pylori in Gastric Diseases.Current topics in microbiology and immunology · 2023Article
- Host Cell Antimicrobial Responses againstInternational journal of molecular sciences · 2022Review
- Vitamin DFrontiers in microbiology · 2022Article
- Antimicrobial peptides and the gut microbiome in inflammatory bowel disease.World journal of gastroenterology · 2021Article
- Alterations in Intestinal Microbiota Composition in Mice Treated With Vitamin D3 or Cathelicidin.Frontiers in oncology · 2021Article
- Cathelicidin preserves intestinal barrier function in polymicrobial sepsis.Critical care (London, England) · 2020Article
- Vitamin D3 InhibitsFrontiers in cellular and infection microbiology · 2020Article
- Vitamin D3 activates the autolysosomal degradation function against Helicobacter pylori through the PDIA3 receptor in gastric epithelial cells.Autophagy · 2019Article
- Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects.Oncology letters · 2018Article
- Antibiotic treatment for Helicobacter pylori: Is the end coming?World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Article
- Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts.Clinical and experimental gastroenterology · 2015Article
- Cathelicidin a potential therapeutic peptide for gastrointestinal inflammation and cancer.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cathelicidin, an antimicrobial peptide of the innate immune system, has been shown to modulate microbial growth, wound healing and inflammation. However, whether cathelicidin controls Helicobacter pylori infection in vivo remains unexplored. This study sought to elucidate the role of endogenous and exogenous mouse cathelicidin (CRAMP) in the protection against H. pylori infection and the associated gastritis in mice. Results showed that genetic ablation of CRAMP in mice significantly increased the susceptibility of H. pylori colonization and the associated gastritis as compared with the wild-type control. Furthermore, replenishment with exogenous CRAMP, delivered via a bioengineered CRAMP-secreting strain of Lactococcus lactis, reduced H. pylori density in the stomach as well as the associated inflammatory cell infiltration and cytokine production. Collectively, these findings indicate that cathelicidin protects against H. pylori infection and its associated gastritis in vivo. Our study also demonstrates the feasibility of using the transformed food-grade bacteria to deliver cathelicidin, which may have potential clinical applications in the treatment of H. pylori infection in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.